MRNA Insider Trading

Insider Ownership Percentage: 11.00%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $65,536,138.45

Moderna Insider Trading History Chart

This chart shows the insider buying and selling history at Moderna by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$100M-$50M$0$50M$100MTotal Insider BuyingTotal Insider Selling

Moderna Share Price & Price History

Current Price: $25.73
Price Change: Price Decrease of -1.99 (-7.18%)
As of 04/3/2025 05:00 PM ET

This chart shows the closing price history over time for MRNA up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
MayJunJulAugSepOctNovDecJanFebMar$27.72Closing price on 04/02/25:

SEC Filings (Institutional Ownership Changes) for Moderna (NASDAQ:MRNA)

75.33% of Moderna stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at MRNA by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$33kbought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$2B$0$2BTotal InflowsTotal Outflows
Moderna logo
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Read More on Moderna

Today's Range

Now: $25.73
Low: $25.70
High: $27.20

50 Day Range

MA: $33.88
Low: $25.73
High: $44.94

52 Week Range

Now: $25.73
Low: $25.62
High: $170.47

Volume

12,752,926 shs

Average Volume

6,973,921 shs

Market Capitalization

$9.95 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.86

Who are the company insiders with the largest holdings of Moderna?

Moderna's top insider shareholders include:
  1. Stephane Bancel (CEO)
  2. Noubar Afeyan (Director)
  3. Stephen Hoge (President)
  4. Shannon Thyme Klinger (Insider)
  5. James M Mock (CFO)
  6. Arpa Garay (Insider)
Learn More about top insider investors at Moderna.